Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CARA
Previous Symbol
CUSIPN/A
Phone203-406-3700
Debt
Debt-to-Equity RatioN/A
Current Ratio4.89
Quick Ratio4.89
Price-To-Earnings
Trailing P/E Ratio-8.36
Forward P/E Ratio-7.52
P/E GrowthN/A
Sales & Book Value
Annual Sales$910,000.00
Price / Sales678.72
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.66 per share
Price / Book5.91
Profitability
EPS (Most Recent Fiscal Year)($1.86)
Net Income$-58,120,000.00
Net MarginsN/A
Return on Equity-70.82%
Return on Assets-50.95%
Miscellaneous
Employees37
Outstanding Shares39,290,000
Market Cap$631.40 million
OptionableOptionable
Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions
What is Cara Therapeutics' stock symbol?
Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."
How were Cara Therapeutics' earnings last quarter?
Cara Therapeutics Inc (NASDAQ:CARA) issued its earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.05. The biopharmaceutical company earned $5.06 million during the quarter, compared to the consensus estimate of $4.72 million. View Cara Therapeutics' Earnings History.
When is Cara Therapeutics' next earnings date?
What price target have analysts set for CARA?
9 analysts have issued twelve-month price objectives for Cara Therapeutics' shares. Their predictions range from $21.00 to $30.00. On average, they expect Cara Therapeutics' share price to reach $26.1111 in the next year. This suggests a possible upside of 66.6% from the stock's current price. View Analyst Price Targets for Cara Therapeutics.
What is the consensus analysts' recommendation for Cara Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics.
What are Wall Street analysts saying about Cara Therapeutics stock?
Here are some recent quotes from research analysts about Cara Therapeutics stock:
- 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (11/21/2018)
- 2. Cantor Fitzgerald analysts commented, "Compelling P2 safety and clinical activity data have been used to guide the design and risk-reduce pivotal P3 studies of IV KORSUVA in CKD-aP hemodialysis pts, from which we expect data in 2019. Our conviction for this program is bolstered by the significant partnership signed with a worldwide provider of hemodialysis services, which we believe validates the clinical and commercial potential. In addition, clinical success in CKD-aP could translate to other indications associated with pruritus, such as chronic liver disease, which should expand KORSUVA’s market opportunity." (10/4/2018)
- 3. HC Wainwright analysts commented, "We view this as a clear positive for the company, as it brings in minimally- dilutive financing ($50M cash plus $20M equity investment at $17/ share), validates our view on Korsuva, and de-risks the U.S. commercial launch. Despite the headline ex-US deal, we’re more focused on the new U.S. arrangement here because we don’t yet include ex-US in our model until we get more clarity on the regulatory and reimbursement landscape (our valuation is all-U.S.), and we assume the U.S. was also the primary value driver here for Vifor Fresenius as well. Vifor Fresenius is a JV of Vifor (VIFN:SW) and Fresenius Medical Care AG (FMS; not covered). We believe Vifor Fresenius is the best possible commercial partner for Cara, with Fresenius itself owning nearly 40% of U.S. dialysis centers." (5/23/2018)
Has Cara Therapeutics been receiving favorable news coverage?
News headlines about CARA stock have trended very positive on Monday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cara Therapeutics earned a media sentiment score of 3.9 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Cara Therapeutics' key competitors?
Some companies that are related to Cara Therapeutics include Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Xencor (XNCR), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Endocyte (ECYT), AnaptysBio (ANAB), Supernus Pharmaceuticals (SUPN), Pacira Pharmaceuticals (PCRX), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD) and Prestige Consumer Healthcare (PBH).
Who are Cara Therapeutics' key executives?
Cara Therapeutics' management team includes the folowing people:
- Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 54)
- Dr. Mani Mohindru, CFO & Chief Strategy Officer (Age 46)
- Dr. Joseph Stauffer, Consultant (Age 52)
- Dr. Michael E. Lewis Ph.D., Co-Founder and Chief Scientific Advisor (Age 66)
- Mr. Scott M. Terrillion, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 55)
Who are Cara Therapeutics' major shareholders?
Cara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.02%), Vanguard Group Inc. (3.95%), Disciplined Growth Investors Inc. MN (2.16%), Nexthera Capital LP (1.88%), FMR LLC (1.60%) and Marshall Wace LLP (1.15%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi, Joseph William Stauffer, Mani Mohindru and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics.
Which institutional investors are selling Cara Therapeutics stock?
CARA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., FMR LLC, C WorldWide Group Holding A S, Virtus ETF Advisers LLC, Bridgeway Capital Management Inc., Disciplined Growth Investors Inc. MN and Credit Suisse AG. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Joseph William Stauffer and Mani Mohindru. View Insider Buying and Selling for Cara Therapeutics.
Which institutional investors are buying Cara Therapeutics stock?
CARA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Nexthera Capital LP, Sphera Funds Management LTD., Opaleye Management Inc., Marshall Wace LLP, EAM Global Investors LLC and EAM Investors LLC. View Insider Buying and Selling for Cara Therapeutics.
How do I buy shares of Cara Therapeutics?
Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cara Therapeutics' stock price today?
One share of CARA stock can currently be purchased for approximately $15.6750.
How big of a company is Cara Therapeutics?
Cara Therapeutics has a market capitalization of $631.40 million and generates $910,000.00 in revenue each year. The biopharmaceutical company earns $-58,120,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Cara Therapeutics employs 37 workers across the globe.
What is Cara Therapeutics' official website?
How can I contact Cara Therapeutics?
Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.
MarketBeat Community Rating for Cara Therapeutics (NASDAQ CARA)
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
